Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2086-2093

  Brisbois, T D ^a   de Kock, I H ^a   Watanabe, S M ^a   Mirhosseini, M ^a   Lamoureux, D C ^a   Chasen, M ^b   MacDonald, N ^c   Baracos, V E ^a   Wismer, W V ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Anorexia drug therapy; Appetite drug effects; Neoplasms complications; Taste olfaction disorders diagnosis; Tetrahydrocannabinol therapeutic use

Indexed keywords

CORTICOSTEROID; DRONABINOL; PLACEBO;

ABDOMINAL CRAMP; ADVANCED CANCER; AGED; APPETITE; APPETITE DISORDER; ARTICLE; BEDTIME DOSAGE; BLOOD CELL COUNT; CALORIC INTAKE; CANADA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPNEA; EDEMA; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HEART BEAT; HUMAN; LEISURE; LOW DRUG DOSE; MACRONUTRIENT; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PAIN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN INTAKE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SLEEP; SLEEP DISORDER; SMELLING DISORDER; TASTE DISORDER; THRUSH; VAGINA DISCHARGE;

EID: 79958253782     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq727     Document Type: Article

References (48)

1. MacDonald N, Easson AM, Mazurak VC et al. Understanding and managing cancer cachexia. J Am Coll Surg 2003; 197: 143-161.
2. Ekert H, Waters KD, Jurk IH et al. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 1979; 2: 657-659.
3. Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302: 135-138.
4. Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994; 10: 14-18.
5. Plasse TF, Gorter RW, Krasnow SH et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695-700.
6. Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-573.
7. Regelson W, Butler JR, Schulz J et al. Delta-9-Tetrahydrocannabinol as an Effective Antidepressant and Appetite-Stimulating Agent in Advanced Cancer Patients. New York: Raven Press 1976.
8. Strasser F, Luftner D, Possinger K et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24: 3394-3400.
9. Williams CM, Rogers PJ, Kirkham TC. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 1998; 65: 343-346.
10. Cota D, Marsicano G, Lutz B et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003; 27: 289-301.
11. Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 1988; 11: 1-14.
12. Abel EL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971; 231: 260-261.
13. Haney M, Gunderson EW, Rabkin J et al. Dronabinol and marijuana in HIVpositive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007; 45: 545-554.
14. Beal JE, Olson R, Laubenstein L et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89-97.
15. Wickham RS, Rehwaldt M, Kefer C et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 1999; 26: 697-706.
16. Hutton JL, Baracos VE, Wismer WV. Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage 2007; 33: 156-165.
17. Shragge JE, Wismer WV, Olson KL, Baracos VE. Shifting to conscious control: psychosocial and dietary management of anorexia by patients with advanced cancer. Palliat Med 2007; 21: 227-233.
18. Bartoshuk LM. Chemosensory alterations and cancer therapies. NCI Monogr 1990; 9: 179-184.
19. Jarrett MM, Scantlebury J, Parker LA. Effect of delta9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiol Behav 2007; 90: 425-430.
20. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325.
21. Czesnik D, Schild D, Kuduz J, Manzini I. Cannabinoid action in the olfactory epithelium. Proc Natl Acad Sci U S A 2007; 104: 2967-2972.
22. Oike H, Wakamori M, Mori Y et al. Arachidonic acid can function as a signaling modulator by activating the TRPM5 cation channel in taste receptor cells. Biochim Biophys Acta 2006; 1761: 1078-1084.
23. Heald AE, Pieper CF, Schiffman SS. Taste and smell complaints in HIV-infected patients. AIDS 1998; 12: 1667-1674.
24. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974; 131: 1121-1123.
25. Unimed. Marinol (Dronabinol) Capsules. In Solvay Pharmaceuticals, Inc., Edition 2003.
26. Shun SC, Lai YH, Hsiao FH. Patient-related barriers to fatigue communication in cancer patients receiving active treatment. Oncologist 2009; 14: 936-943.
27. The Cochrane Collaboration, Patient Reported Outcomes Measurement Group. In http://www.cochrane-pro-mg.org/Objective.html (5 July 2009, date last accessed).
28. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008; 26: 1355-1363.
29. Cardello AV, Schutz HG, Lesher LL, Merrill E. Development and testing of a labeled magnitude scale of perceived satiety. Appetite 2005; 44: 1-13.
30. Brisbois-Clarkson TD, McIsaac TM, Goonewardene LA, Wismer WV. Modification and validation of a Macronutrient Preference Checklist for use in North America. Appetite 2009; 53: 461-464.
31. Larkin FA, Metzner HL, Guire KE. Comparison of three consecutive-day and three random-day records of dietary intake. J Am Diet Assoc 1991; 91: 1538-1542.
32. Ribaudo JM, Cella D, Hahn EA et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 2000; 9: 1137-1146.
33. Bruera E, Kuehn N, Miller MJ et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7: 6-9.
34. Ware MA, Doyle CR, Woods R et al. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003; 102: 211-216.
35. Armijo-Olivo S, Warren S, Magee D. Intention to treat analysis, compliance, dropouts and how to deal with missing data in clinical research: a review. Physical Therapy Reviews 2008; 14: 36-49.
36. SAS Institute. Statistical Analysis System for Windows, Version 8.2. In Edition 8.2. Cary, NC: Institute Inc 1999[39].
37. Steel R, Torrie J, Da D. Principles and Procedures of Statistics a Biometrical Approach. New York: McGraw-Hill, Inc 1997.
38. Freund RJ, Wilson WJ. Statistical Methods. San Diego, CA: Academic Press 2003.
39. Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2008; 16: 275-283.
40. Steinbach S, Hummel T, Bohner C et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 2009; 27: 1899-1905.
41. Nail R, Gunderson E, Kolb D. Motives for drug use among light and heavy users. J Nerv Ment Dis 1974; 159: 131-136.
42. Roth W, Tinklenberg J, Kopel B. Subjective benefits and drawbacks of marihuana and alcohol. In Cohen S, Stillman R (eds), The Therapeutic Potential of Marihuana, Edition. New York: Plenum Medical Book Co. 1976; 255-269.
43. Robson P. Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 2005; 168: 719-756.
44. Noyes RJ, Brunk S, Avery D, Canter A. Psychological effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients. Compr Psychiatry 1976; 17: 641-646.
45. Mela DJ. Food choice and intake: the human factor. Proc Nutr Soc 1999; 58: 513-521.
46. Walsh D, Kirkova J, Davis MP. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. J Pain Symptom Manage 2005; 30: 493-495.
47. Sanchez-Lara K, Sosa-Sanchez R, Green-Renner D et al. Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J 2010; 9: 15.
48. Mattes RD, Shaw LM, Engelman K. Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. Chem Senses 1994; 19: 125-140.